Sitryx Therapeutics Limited (Sitryx) is a UK-based biopharmaceutical company focused on discovering and developing small-molecule medicines that modulate immune cell metabolism (immunometabolism). Its research aims to restore immune balance to treat autoimmune and inflammatory diseases, with potential applications in oncology.
The company employs structure-guided drug design and translational immunology to advance a preclinical pipeline of orally administered therapies targeting metabolic checkpoints in key immune cells. Sitryx is privately held and engages in strategic collaborations with larger pharmaceutical organizations to progress its programs from discovery toward clinical development.
None yet. When a new project in the record names Sitryx as owner, partner or investor, it shows here.
Boehringer gains exclusive rights to Sitryx's preclinical program for autoimmune diseases, with potential payments over $500M and tiered royalties on future sales.
